The approval of ticagrelor, an anti-platelet drug marketed as Brilinta in the US and Brilique in Europe, has been mired in controversy since the publication of the PLATO trial. This landmark clinical trial, which led to the drug's worldwide approval, has faced intense scrutiny over the
Hodgkin lymphoma, a rare but treatable blood cancer, primarily impacts younger individuals aged 20-40. Effective treatment is crucial, but so is the consideration of long-term health and quality of life for patients. Recent advancements in chemotherapy regimens have shown promise in reducing
The PROSPECT-Lung trial has officially commenced, heralding a significant advance in the quest to enhance treatment strategies for patients with resectable non-small cell lung cancer (NSCLC). This trial marks the inaugural endeavor of the newly established National Cancer Institute (NCI) Clinical
In a groundbreaking advancement, MIT researchers have developed a revolutionary technique in the realm of metabolic imaging. This noninvasive method utilizes laser light to study living cells, providing valuable insights into disease progression and treatment responses. Traditional metabolic
The findings from the late-breaking research presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition have brought new insights into the treatment of mantle cell lymphoma (MCL). The phase 3 study EA4151, conducted by the ECOG-ACRIN Cancer Research Group, investigated
Hereditary hemochromatosis is a genetic condition characterized by excessive iron absorption and storage due to mutations in the HFE gene, particularly the C282Y variant. This condition is especially prevalent in Europe, where many individuals are homozygous for the C282Y mutation. Despite the
